Among different candidates, we identified the essentiality of EZH2 specifically in hematological cancer cell lines (Fig. 4, available as supplementary data at Bioinformatics Advances online) in all iMR models build on TRRUST. This evidence concerns the gene EZH2 and hematopoietic and lymphoid cell neoplasm.